BioNTech, the German biotech that partnered with Pfizer to develop the first COVID-19 vaccine to earn the FDA’s emergency use authorization, is now using mRNA to tackle another disease: malaria. The ...

FILE PHOTO: Test tubes are seen in front of a displayed Biontech logo in this illustration BERLIN (Reuters) -BioNTech on Friday initiated an early-stage study to evaluate its experimental malaria ...

BERLIN, Dec 23 (Reuters) - BioNTech 22UAy.DE has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on ...

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the company's Investigational New Drug application and mid-stage trial evaluating ...

Backed by the eradicateMalaria initiative, German company BioNTech announces a malaria project consisting of the development of an mRNA-based vaccine against the disease and the evaluation of mRNA ...

MAINZ, Germany/OSLO, Norway, May 29, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) are expanding their strategic ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on BioNTech SE’s (NASDAQ:BNTX) Investigational New Drug application (IND) and the related Phase 1/2a trial evaluating the ...

As various efforts to produce next-generation vaccines in Africa are being carried forward by the likes of the World Health Organization (WHO) and the Bill & Melinda Gates Foundation, BioNTech is ...

Investing.com – BioNTech (NASDAQ:BNTX) stock rose more than 3% Monday following the launch of the company’s ‘Project Malaria’ which aims to develop a vaccine to prevent malaria in Africa. The vaccine ...

BERLIN (AP) — Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria. The Germany-based company, which developed the ...

BERLIN, Dec 23 (Reuters) - BioNTech 22UAy.DE on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said. The Phase 1 trial is expected ...